We validated our findings in UWG02CTCs using the clinically approved PI3K inhibitor alpelisib, currently approved in combination with hormone therapy in advanced, HER2-negative, PIK3CA-mutated breast cancer [26]. This evidence concerns the gene PIK3CA and breast carcinoma.